Working… Menu
Trial record 52 of 801 for:    LENALIDOMIDE AND cells

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02446236
Recruitment Status : Recruiting
First Posted : May 18, 2015
Last Update Posted : October 7, 2019
Information provided by (Responsible Party):
Hackensack Meridian Health

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2022
Wu A, Scheffler MR. Multi-dose phamacokinetics and safety of CC-5013 in 15 multiple myeloma patients. J Clin Oncol.;22:141s, 2004